Vaxcyte
PCVX
60 hedge funds and large institutions have $1.86B invested in Vaxcyte in 2020 Q3 according to their latest regulatory filings, with 34 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 12 closing their positions.
183% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 12
65% more capital invested
Capital invested by funds: $1.13B → $1.86B (+$731M)
58% more funds holding
Funds holding: 38 → 60 (+22)
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
0.13% less ownership
Funds ownership: 74.29% → 74.16% (-0.13%)
36% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$66.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$52.7M |
| 3 |
BlackRock
New York
|
+$36.8M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$12.5M |
| 5 |
State Street
Boston,
Massachusetts
|
+$10.9M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$30.8M |
| 2 |
Janus Henderson Group
London,
|
-$21.1M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$19.8M |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
-$14.4M |
| 5 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
-$9.18M |
PCVX Hedge Fund Activity: Q3 2020 in Review
60 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Vaxcyte (PCVX) for Q3 2020, worth a combined $1.86B — up 65% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new PCVX positions and 12 closed out — a net gain of 22 holders — while 7 added to existing stakes and 11 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $66.5M. The largest seller was Millennium Management, cutting an estimated $30.8M.
- 60 institutional investors held Vaxcyte (PCVX) as of Q3 2020, up from 38 in Q2 2020.
- Funds reported $1.86B of Vaxcyte stock for Q3 2020, up 65% quarter-over-quarter.
- 34 funds opened new Vaxcyte positions in Q3 2020 and 12 closed out, a net change of +22 holders.
- The largest Vaxcyte buyer in Q3 2020 was Fidelity Investments, an estimated $66.5M added.
- The largest Vaxcyte seller in Q3 2020 was Millennium Management, an estimated $30.8M sold.
Based on aggregated 13F filings for Q3 2020.